Wolf-karsten W.-k. Hofmann

Wolf-karsten W.-k. Hofmann's AcademicInfluence.com Rankings

Biology

#12005

World Rank

#15451

Historical Rank

Genetics

#1309

World Rank

#1411

Historical Rank

Molecular Biology

#1906

World Rank

#1937

Historical Rank

Biochemistry

#2020

World Rank

#2162

Historical Rank

biology Degrees

Download Badge

Biology

Wolf-karsten W.-k. Hofmann's Degrees

PhD Molecular Biology University of California, Berkeley

Why Is Wolf-karsten W.-k. Hofmann Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Wolf-karsten W.-k. Hofmann's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Frequent pathway mutations of splicing machinery in myelodysplasia (2011) (1799)
Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. (2009) (1615)
Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. (2004) (981)
Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. (2005) (796)
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease (2010) (732)
Human haematopoietic stem cell lineage commitment is a continuous process (2017) (631)
Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. (2010) (566)
Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. (2005) (472)
HMG-CoA Reductase Inhibitors Reduce Senescence and Increase Proliferation of Endothelial Progenitor Cells via Regulation of Cell Cycle Regulatory Genes (2003) (405)
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) (2012) (401)
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. (2012) (388)
Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. (2010) (379)
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. (2018) (378)
Antioxidative stress-associated genes in circulating progenitor cells: evidence for enhanced resistance against oxidative stress. (2004) (349)
Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. (2014) (347)
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms (2012) (325)
Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. (2002) (309)
Cathepsin L is required for endothelial progenitor cell–induced neovascularization (2005) (300)
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. (2009) (289)
Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. (2002) (274)
Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. (2011) (270)
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. (2011) (262)
Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. (2006) (227)
Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. (2002) (226)
Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study (2002) (209)
Comprehensive mutational profiling in advanced systemic mastocytosis. (2013) (208)
FOXO‐dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells (2005) (203)
BCL6 enables Ph+ acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition (2011) (200)
Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. (2001) (196)
A Differentiation Checkpoint Limits Hematopoietic Stem Cell Self-Renewal in Response to DNA Damage (2012) (193)
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis (2010) (186)
Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. (2013) (186)
Long-Term Control of HIV by CCR 5 Delta 32 / Delta 32 Stem-Cell Transplantation (2009) (175)
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia (2011) (171)
Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. (2009) (169)
The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. (2009) (169)
Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. (2011) (167)
Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. (2005) (163)
Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. (2011) (158)
An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase (2008) (156)
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. (2015) (153)
Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. (2007) (150)
HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells. (2009) (149)
Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia (2012) (148)
A Differentiation Checkpoint Limits Hematopoietic Stem Cell Self-Renewal in Response to DNA Damage (2014) (147)
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis (2016) (145)
Pre–B cell receptor–mediated cell cycle arrest in Philadelphia chromosome–positive acute lymphoblastic leukemia requires IKAROS function (2009) (144)
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions (2017) (141)
IL-18 Activates STAT3 in the Natural Killer Cell Line 92, Augments Cytotoxic Activity, and Mediates IFN-γ Production by the Stress Kinase p38 and by the Extracellular Regulated Kinases p44erk-1 and p42erk-21 (2000) (137)
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes (2004) (137)
Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. (2003) (136)
Gene Expression Profile of Serial Samples of Transformed B-Cell Lymphomas (2003) (133)
The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis (2013) (125)
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib (2014) (123)
The C/EBPδ tumor suppressor is silenced by hypermethylation in acute myeloid leukemia (2007) (118)
High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. (2006) (117)
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study (2012) (114)
Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors (2002) (113)
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event (2014) (110)
Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. (2003) (109)
Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations (2012) (108)
Inhibitory effect of imatinib on normal progenitor cells in vitro. (2004) (106)
The hematology of anorexia nervosa. (2009) (105)
Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. (2013) (103)
Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. (2016) (103)
Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1–transformed acute lymphoblastic leukemia cells (2006) (101)
Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. (2007) (100)
Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. (2011) (100)
FLT3 Mutations in Early T-Cell Precursor ALL Characterize a Stem Cell Like Leukemia and Imply the Clinical Use of Tyrosine Kinase Inhibitors (2013) (98)
Expression of C/EBPbeta from the C/ebpalpha gene locus is sufficient for normal hematopoiesis in vivo. (2002) (95)
Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. (2015) (95)
Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. (2012) (90)
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib (2014) (89)
Mimicry of a constitutively active pre–B cell receptor in acute lymphoblastic leukemia cells (2005) (89)
Dlk1 in normal and abnormal hematopoiesis (2005) (88)
The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemia. (2011) (88)
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia (2016) (88)
The Survivin Isoform Survivin-3B is Cytoprotective and can Function as a Chromosomal Passenger Complex Protein (2007) (87)
Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-β-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study. (2016) (85)
Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. (2011) (85)
Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. (2007) (81)
Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. (2017) (81)
Infection of cultured intestinal epithelial cells with severe acute respiratory syndrome coronavirus (2004) (80)
Disruption of LTBP-4 function reduces TGF-β activation and enhances BMP-4 signaling in the lung (2004) (79)
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. (2011) (76)
Myelodysplastic syndromes: molecular pathogenesis and genomic changes (2008) (75)
The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. (2007) (73)
Cell Cycle Alterations in the Blastoid Variant of Mantle Cell Lymphoma (MCL-BV) as Detected by Gene Expression Profiling of Mantle Cell Lymphoma (MCL) and MCL-BV (2003) (73)
Antileukemic activity of the HSP70 inhibitor pifithrin-μ in acute leukemia (2011) (72)
Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia (2009) (71)
Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload (2012) (70)
DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding. (2013) (70)
C/EBPδ expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation (2005) (70)
Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes (2015) (69)
Discovery of epigenetically silenced genes in acute myeloid leukemias (2007) (68)
Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples (2012) (68)
Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia. (2011) (66)
SETBP1 mutation analysis in 944 patients with MDS and AML (2013) (65)
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet (2015) (65)
Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias. (2001) (64)
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm (2017) (64)
Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. (2005) (63)
Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. (2014) (62)
Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization (2013) (61)
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML (2015) (61)
Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome (2009) (60)
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis (2016) (60)
Myelodysplastic syndromes: clinical features. (1996) (58)
Development of Novel PCR Assays To Detect Azole Resistance-Mediating Mutations of the Aspergillus fumigatus cyp51A Gene in Primary Clinical Samples from Neutropenic Patients (2012) (57)
High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. (2010) (56)
Diagnostic Performance of an Aspergillus-Specific Nested PCR Assay in Cerebrospinal Fluid Samples of Immunocompromised Patients for Detection of Central Nervous System Aspergillosis (2013) (55)
Normalization of coronary blood flow in the infarct-related artery after intracoronary progenitor cell therapy: (2006) (55)
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia (2004) (55)
Transcriptional Profiling of Human Hematopoiesis During In Vitro Lineage‐Specific Differentiation (2005) (55)
C/EBP-β, C/EBP-δ, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies (2002) (54)
Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks (2006) (53)
Mechanisms of Resistance to STI571 (Imatinib) in Philadelphia-chromosome Positive Acute Lymphoblastic Leukemia (2004) (53)
Characterization of the transcriptional regulatory region of the human WT1 gene. (1993) (52)
Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. (2010) (52)
DNA repair gene O6‐methylguanine‐DNA methyltransferase: Promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors (2003) (52)
MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis (2019) (51)
Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation. (2018) (51)
Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors (2002) (51)
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS) (2016) (50)
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group (2012) (50)
Incidence of Cyp51 A Key Mutations in Aspergillus fumigatus—A Study on Primary Clinical Samples of Immunocompromised Patients in the Period of 1995–2013 (2014) (49)
Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics (2018) (48)
Prediction of qualitative outcome of oligonucleotide microarray hybridization by measurement of RNA integrity using the 2100 Bioanalyzer™ capillary electrophoresis system (2009) (45)
BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia (2010) (45)
Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia (2010) (44)
Altered Apoptosis Pathways in Mantle Cell Lymphoma (2004) (43)
KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance (2015) (43)
Identifying progression‐associated genes in adult T‐cell leukemia/lymphoma by using oligonucleotide microarrays (2004) (43)
Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy (2011) (41)
PP2A regulatory subunit Bα controls endothelial contractility and vessel lumen integrity via regulation of HDAC7 (2013) (40)
Detection of invasive pulmonary aspergillosis in critically ill patients by combined use of conventional culture, galactomannan, 1‐3‐beta‐D‐glucan and Aspergillus specific nested polymerase chain reaction in a prospective pilot study (2018) (40)
SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. (2010) (40)
Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors (2015) (40)
Analysis of NUP98/NSD1 translocations in adult AML and MDS patients (2013) (39)
Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG (2011) (39)
Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis (2018) (39)
High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. (2011) (39)
Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group (2010) (38)
Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor (1999) (38)
Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. (2018) (38)
Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia (2017) (37)
Single-cell proteo-genomic reference maps of the hematopoietic system enable the purification and massive profiling of precisely defined cell states (2021) (37)
Identification of invasive fungal diseases in immunocompromised patients by combining an Aspergillus specific PCR with a multifungal DNA‐microarray from primary clinical samples (2015) (37)
Analysis of the CHK2 Gene in Lymphoid Malignancies (2001) (37)
RARβ2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia (2004) (37)
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements (2013) (37)
Tracing the Pre-B to Immature B Cell Transition in Human Leukemia Cells Reveals a Coordinated Sequence of Primary and Secondary IGK Gene Rearrangement, IGK Deletion, and IGL Gene Rearrangement1 (2005) (36)
C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. (2002) (36)
DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation. (2007) (36)
The effect of the CCR5-delta32 deletion on global gene expression considering immune response and inflammation (2011) (35)
Myelodysplastic syndrome. (2005) (35)
Aspergillus PCR-Based Investigation of Fresh Tissue and Effusion Samples in Patients with Suspected Invasive Aspergillosis Enhances Diagnostic Capabilities (2013) (35)
HERV-E-Mediated Modulation of PLA2G4A Transcription in Urothelial Carcinoma (2012) (34)
Activating CBL mutations are associated with a distinct MDS/MPN phenotype (2012) (34)
A ‘telomere-associated secretory phenotype’ cooperates with BCR-ABL to drive malignant proliferation of leukemic cells (2014) (34)
Aberrant methylation in promoter-associated CpG islands of multiple genes in acute lymphoblastic leukemia. (2006) (34)
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase (2017) (34)
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes (2012) (34)
Molecular mechanisms involved in the progression of myelodysplastic syndrome. (2010) (33)
Methylation Analysis of Cell Cycle Control Genes in Adult T-Cell Leukemia/Lymphoma (2001) (33)
Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein a in myelodysplastic syndromes and acute myeloid leukemias (2002) (33)
Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis (2019) (33)
Angiotensin-Converting Enzyme (ACE) Inhibitors Modulate Cellular Retinol-Binding Protein 1 and Adiponectin Expression in Adipocytes via the ACE-Dependent Signaling Cascade (2009) (32)
RTP801 is a novel retinoic acid-responsive gene associated with myeloid differentiation. (2007) (32)
Loss of genomic imprinting of insulin-like growth factor 2 is strongly associated with cellular proliferation in normal hematopoietic cells. (2002) (32)
Management of elderly patients with acute promyelocytic leukemia: progress and problems (2013) (32)
Patients with malignant hematological disorders treated on a palliative care unit: prognostic impact of clinical factors (2014) (31)
Expression of interleukin 15 in primary adult acute lymphoblastic leukemia (2010) (31)
Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes. (2000) (31)
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1‐JAK2, BCR‐JAK2 and ETV6‐ABL1 fusion genes (2020) (31)
The BCR-ABL1 Kinase Bypasses Selection for the Expression of a Pre–B Cell Receptor in Pre–B Acute Lymphoblastic Leukemia Cells (2004) (30)
Transcriptional down-regulation of the Wnt antagonist SFRP1 in haematopoietic cells of patients with different risk types of MDS. (2010) (30)
Increase of DNA damage and alteration of the DNA damage response in myelodysplastic syndromes and acute myeloid leukemias. (2017) (30)
Cancer Patients and Advance Directives: A Survey of Patients in a Hematology and Oncology Outpatient Clinic (2013) (30)
Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571 (2006) (29)
ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells (2013) (29)
Mutation analysis of transferrin-receptor 2 in patients with atypical hemochromatosis. (2002) (29)
Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia‐associated myeloproliferative neoplasms (2015) (29)
Immunofluorescence Microscopy of γH2AX and 53BP1 for Analyzing the Formation and Repair of DNA Double-strand Breaks. (2017) (29)
Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy (2009) (29)
The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells. (2004) (28)
Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms. (2009) (28)
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV (2018) (27)
Methylation analysis of asparagine synthetase gene in acute lymphoblastic leukemia cells (2006) (27)
Zeiher Normalization of coronary blood flow in the infarct-related artery after intracoronary progenitor cell therapy : Intracoronary Doppler substudy of the TOPCARE-AMI trial (26)
Diagnostic Performance of Contrast Enhanced Pulmonary Computed Tomography Angiography for the Detection of Angioinvasive Pulmonary Aspergillosis in Immunocompromised Patients (2017) (26)
Epigenetic dysregulation of GATA1 is involved in myelodysplastic syndromes dyserythropoiesis (2012) (26)
Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation. (2013) (26)
Clonal Heterogeneity in Growth Kinetics of CD34+CD38− Human Cord Blood Cells In Vitro Is Correlated with Gene Expression Pattern and Telomere Length (2005) (25)
Efficacy and Pharmacologic Data of Second-Generation Tyrosine Kinase Inhibitor Nilotinib in BCR-ABL-Positive Leukemia Patients with Central Nervous System Relapse after Allogeneic Stem Cell Transplantation (2014) (25)
Loss of H19 imprinting in adult T‐cell leukaemia/lymphoma (2007) (25)
Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes. (1999) (25)
Direct comparison of galactomannan performance in concurrent serum and bronchoalveolar lavage samples in immunocompromised patients at risk for invasive pulmonary aspergillosis (2016) (24)
Defective Megakaryocytic Development in Myelodysplastic Syndromes (2000) (24)
Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor α levels (2000) (23)
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML) (2000) (23)
Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation (2016) (23)
Fine needle aspiration and core needle biopsy in the diagnosis of lymphadenopathy of unknown aetiology (2012) (23)
Skewed X-inactivation patterns in ageing healthy and myelodysplastic haematopoiesis determined by a pyrosequencing based transcriptional clonality assay (2013) (23)
Takotsubo Cardiomyopathy after Systemic Consolidation Therapy with High-Dose Intravenous Cytarabine in a Patient with Acute Myeloid Leukemia (2014) (23)
Transforming growth factor-beta1 interferes with thrombopoietin-induced signal transduction in megakaryoblastic and erythroleukemic cells. (2001) (22)
Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance. (2015) (22)
Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group (2015) (21)
Genome-Wide Mapping Of Copy Number Variations using SNP Arrays (2009) (21)
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV (2014) (21)
Expression of IGFBP7 in acute leukemia is regulated by DNA methylation (2011) (21)
Identification and functional characterization of imatinib‐sensitive DTD1‐PDGFRB and CCDC88C‐PDGFRB fusion genes in eosinophilia‐associated myeloid/lymphoid neoplasms (2014) (21)
Advances in the treatment of acute myeloid leukemia: From chromosomal aberrations to biologically targeted therapy (2008) (21)
Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4 (2005) (20)
The Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia: Final Report on 3252 Cases from the International MILE Study Group (2008) (20)
Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion Genes (2015) (20)
Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4 (2005) (20)
Cumulative radiation exposure from imaging procedures and associated lifetime cancer risk for patients with lymphoma. (2016) (20)
Assessment of Aspergillus‐specific PCR as a screening method for invasive aspergillosis in paediatric cancer patients and allogeneic haematopoietic stem cell recipients with suspected infections (2014) (20)
Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study. (2013) (19)
Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients (2018) (19)
Epigenetic regulation of PAX5 expression in acute T-cell lymphoblastic leukemia. (2011) (19)
Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation. (2020) (19)
Epigenetic control of differential expression of specific ERG isoforms in acute T-lymphoblastic leukemia. (2009) (19)
Mutation Analysis of hCDC4 in AML Cells Identifies a New Intronic Polymorphism (2006) (19)
The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories (2012) (19)
Impact of centralized evaluation of bone marrow histology in systemic mastocytosis (2016) (18)
Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment‐Free Remission in a EURO‐SKI Subtrial (2018) (18)
RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia. (2004) (18)
Genome-wide DNA-mapping of CD34+ cells from patients with myelodysplastic syndrome using 500K SNP arrays identifies significant regions of deletion and uniparental disomy. (2009) (18)
Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer -- impact on long-term quality of life. (2012) (18)
Dosage effect of zero to three functional LBR-genes in vivo and in vitro. (2010) (18)
Importance of adequate diagnostic work-up for correct diagnosis of advanced systemic mastocytosis. (2020) (17)
KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis (2019) (17)
Detection of Aberrant Gene Expression in CD34+ Hematopoietic Stem Cells from Patients with Agnogenic Myeloid Metaplasia Using Oligonucleotide Microarrays (2005) (17)
Functional analysis of a novel DNA polymorphism of a tandem repeated sequence in the asparagine synthetase gene in acute lymphoblastic leukemia cells. (2009) (17)
Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia (2002) (17)
Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy (2015) (17)
Corrigendum: Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia (Leukemia (2016) 30 (1672-1681) DOI: 10.1038/leu.2016.69) (2016) (17)
Expression of the adaptor protein Lnk in leukemia cells. (2009) (17)
Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome - Emphasis on optimized dosing schedules and new formulations. (2015) (16)
DNA Damage and DNA Damage Response in Chronic Myeloid Leukemia (2020) (16)
A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition (2015) (16)
The evolving landscape of new diagnostic tests for invasive aspergillosis in hematology patients: strengths and weaknesses (2017) (16)
Detection of centrosome aberrations in disease‐unrelated cells from patients with tumor treated with tyrosine kinase inhibitors (2010) (16)
The Proteolytic Activity of Separase in BCR-ABL-Positive Cells Is Increased by Imatinib (2012) (16)
In acute promyelocytic leukemia (APL) low BAALC gene expression identifies a patient group with favorable overall survival and improved relapse free survival. (2013) (16)
In vivo drug-response in patients with leukemic non-Hodgkin's lymphomas is associated with in vitro chemosensitivity and gene expression profiling. (2006) (16)
Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5‐azacitidine (2017) (15)
Frequent loss of heterozygosity in the region of D1S450 at 1p36.2 in myelodysplastic syndromes. (2001) (15)
SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3 (2012) (15)
Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions (2013) (15)
Prognostic importance of expression of the Wilms’ tumor 1 gene in newly diagnosed acute promyelocytic leukemia (2015) (14)
Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox. (2011) (14)
Whole-body CT for lymphoma staging: feasibility of halving radiation dose and risk by iterative image reconstruction. (2014) (14)
Centrosome aberrations in bone marrow cells from patients with myelodysplastic syndromes correlate with chromosomal instability (2012) (14)
Mast cell sarcoma mimicking metastatic colon carcinoma (2014) (14)
Cumulative radiation exposure from imaging procedures and associated lifetime cancer risk for patients with lymphoma (2016) (14)
Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide. (2015) (14)
BCL 6-mediated repression of p 53 is critical for leukemia stem cell survival in chronic myeloid leukemia (2011) (14)
Evaluating the use of PCR for diagnosing invasive aspergillosis (2017) (14)
Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations (2020) (14)
Molecular and Cytogenetic Response After 3 Months of Imatinib Treatment Is Predictive for the Risk of Disease Progression and Death in Newly Diagnosed Chronic Myeloid Leukemia Patients – a Follow-up Analysis of the German CML Study IV (2011) (13)
Allogeneic hematopoietic cell transplantation without fluconazole and fluoroquinolone prophylaxis (2015) (13)
Biomarker‐based diagnostic work‐up of invasive pulmonary aspergillosis in immunocompromised paediatric patients – is Aspergillus PCR appropriate? (2016) (13)
Multidrug‐resistant organisms in allogeneic hematopoietic cell transplantation (2017) (13)
Important features of myelodysplastic syndrome (2002) (13)
Impact of persistent cytomegalovirus infection on human neuroblastoma cell gene expression. (2005) (12)
WT1-Peptide Vaccination Shows High Immunogenicity and Clinical Activity in Patients with Acute Myeloid Leukemia. (2005) (12)
Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia (2015) (12)
Additional Mutations in SRSF2, ASXL1 and/or RUNX1 Identify a High Risk Group of Patients with KIT D816V+ Advanced Systemic Mastocytosis (2015) (12)
Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells (2007) (12)
A molecular risk score integrating BAALC, ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia. (2015) (12)
Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin (1998) (12)
TGFβ-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34+ cells from healthy donors, but not from patients with AML after MDS (2001) (12)
Molecular and phenotypic diversity of CBLmutated juvenile myelomonocytic leukemia (2020) (11)
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (2021) (11)
High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia (2013) (11)
An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis (2020) (11)
Long term outcome of patients with steroid‐refractory acute intestinal graft versus host disease after treatment with pentostatin (2011) (11)
Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS. (2017) (11)
Leukocyte DNA damage after reduced and conventional absorbed radiation doses using 3rd generation dual-source CT technology (2016) (11)
Assessment of acute intestinal graft versus host disease by abdominal magnetic resonance imaging at 3 Tesla (2014) (11)
ICSBP promoter methylation in myelodysplastic syndromes and acute myeloid leukaemia (2011) (10)
High correlation of the proteome patterns in bone marrow and peripheral blood blast cells in patients with acute myeloid leukemia (2009) (10)
Measurement of Separase Proteolytic Activity in Single Living Cells by a Fluorogenic Flow Cytometry Assay (2015) (10)
Coinfection of Pneumocystis jirovecii and Invasive Pulmonary Aspergillosis in an Immunocompromised Patient: A Diagnostic Challenge (2013) (10)
Platelet glycoprotein expression in patients with myelodysplastic syndrome. (2000) (10)
Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials (2019) (10)
Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT 3 A mutations (2013) (10)
c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemia (2016) (10)
Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies (2019) (10)
Meeting report: Vienna 2008 Workshop of the German–Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes (2009) (10)
Magnetic resonance imaging reveals distinct bone marrow patterns in indolent and advanced systemic mastocytosis (2019) (9)
Characteristics, Treatment and Prognostic Factors of Patients with Gynaecological Malignancies Treated in a Palliative Care Unit at a University Hospital (2013) (9)
Increased separase activity and occurrence of centrosome aberrations concur with transformation of MDS (2018) (9)
Statistical analysis of gene expression data (2001) (9)
Identification of defects in the transcriptional program during lineage-specific in vitro differentiation of CD34(+) cells selected from patients with both low- and high-risk myelodysplastic syndrome. (2010) (9)
Human haematopoietic stem cell lineage commitment is a continuous process (2017) (9)
The Role of Microrna-196a-1 and Microrna-196b in Acute T-Lymphoblastic Leukemia and Acute Myeloid Leukemia. (2009) (9)
Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia (2014) (9)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: Update on the Survival Outcome Following Allogeneic HSCT after Imatinib Failure; Results of the German CML Study IV (2008) (9)
Myelodysplastic syndromes. (2004) (9)
Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. (2022) (9)
Gene expression profiling by microarrays : clinical implications (2006) (8)
High Rate of FLT3 Mutations In Adult ETP-ALL. (2010) (8)
Erratum: Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia (2016) (8)
Accumulation of DNA damage and alteration of the DNA damage response in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia (2018) (8)
Myelodysplastic Syndromes: Aspects of Current Medical Care and Economic Considerations in Germany (2008) (8)
Disruption of LTBP-4 function reduces TGF- (cid:1) activation and enhances BMP-4 signaling in the lung (2004) (8)
The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience (2014) (8)
Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide (2019) (7)
Course of colonization by multidrug-resistant organisms after allogeneic hematopoietic cell transplantation (2018) (7)
Secondary Malignancies in CML Patients – Data From the German CML Study IV (2012) (7)
Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial (2017) (7)
Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis (2022) (7)
Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial. (2004) (7)
Influence of the insertion site on central venous catheter-related complications in patients undergoing allogeneic hematopoietic cell transplantation. (2020) (7)
Does Physical Activity Improve Quality of Life in Cancer Patients Undergoing Chemotherapy? (2015) (7)
Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines (2018) (7)
Clinical and immune responses of WT1-peptide vaccination in patients with acute myeloid leukemia. (2006) (7)
Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia (2014) (7)
Bone marrow derived stromal cells from myelodysplastic syndromes are altered but not clonally mutated in vivo (2021) (7)
Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group (2015) (7)
Mammalian‐target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D‐MDS) (2016) (7)
A Multi-Center and Multi-National Program To Assess the Clinical Accuracy of the Molecular Subclassification of Leukemia by Gene Expression Profiling. (2005) (7)
Validation of a Molecular Risk Score for Prognosis of Patients With Acute Promyelocytic Leukemia Treated With All‐trans Retinoic Acid and Chemotherapy‐containing Regimens (2017) (6)
Topical Treatment of Acyclovir-Resistant Herpes Simplex Virus Stomatitis after Allogeneic Hematopoietic Cell Transplantation (2020) (6)
Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto‐oncogene, receptor tyrosine kinase (KIT) D816V mutations (2021) (6)
Comorbidity, Measured By The Charlson Index, Has No Negative Impact On Remission In Patients With Chronic Myeloid Leukemia: Results Of The Randomized CML-Study IV (2013) (6)
Gene expression profiling of normal hematopoietic progenitor cells under treatment with imatinib in vitro (2005) (6)
Molecular Analysis of Desmoid Tumors with a High-Density Single-Nucleotide Polymorphism Array Identifies New Molecular Candidate Lesions (2012) (6)
Detection of differential mitotic cell age in bone marrow CD34(+) cells from patients with myelodysplastic syndrome and acute leukemia by analysis of an epigenetic molecular clock DNA signature. (2010) (5)
Optimizing Early Prediction Of Outcome In CML Using The Exact Decline Of BCR-ABL Transcript Levels Within 3 Months Of Imatinib Treatment As a Prognostic Marker (2013) (5)
Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects (2017) (5)
The insertion site is the main risk factor for central venous catheter‐related complications in patients with hematologic malignancies (2022) (5)
Aspergillus specific nested PCR from the site of infection is superior to testing concurrent blood samples in immunocompromised patients with suspected invasive aspergillosis (2019) (5)
The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemia (2018) (5)
Immunosuppression for Patients with Low and Intermediate Risk Myelodysplastic Syndrome: A Prospective Randomized Multicenter Trial Comparing Antithymocyte Globulin + Cyclosporine with Best Supportive Care: SAKK 33/99. (2007) (5)
An international multi-center study to assess the clinical accuracy of the molecular subclassification of leukemia by gene expression profiling. (2006) (5)
Murine M2-10B4 and SL/SL cell lines differentially affect the balance between CD34+ cell expansion and maturation (2001) (5)
Adjuvant CD49d Blockade Eradicates Chemoresistant ALL (2010) (4)
Quantitative quality control of microarray experiments: toward accurate gene expression measurements (2001) (4)
Key Data Elements in Myeloid Leukemia (2016) (4)
The BCR-ABL 1 Kinase Bypasses Selection for the Expression of a Pre – B Cell Receptor in Pre – B Acute Lymphoblastic Leukemia Cells (2004) (4)
The Extent of Labile Plasma Iron (LPI) Predicts for Non-Relapse-Mortality (NRM) in AML and MDS Patients with Systemic Iron Overload Undergoing Allogenic Stem Cell Transplantation Results of the Prospective, German-Austrian Allive Trial (2015) (4)
Genomic imprinting of insulin-like growth factor 2 (IGF-2) in chronic synovitis. (2007) (4)
In Analogy to AML, MDS Can be Sub-Classified By Ancestral Mutations (2014) (4)
CXCR 4 expression is associated with survival in familial chronic lymphocytic leukemia , but CD 38 expression (2002) (4)
A Phase I Study of a Combination of 5-Azacyitidine Followed by Lenalidomide In High-Risk MDS or AML Patients with Chromosome 5 Abnormalities – Interim Results of the “AZALE” Trial (2010) (4)
MutaSeq reveals the transcriptomic consequences of clonal evolution in acute myeloid leukemia (2018) (4)
Safety and Efficacy of a Combination of 5-Azacitidine Followed by Lenalidomide in High-Risk MDS or AML Patients with Del(5q) Cytogenetic Abnormalities – Results of the “AZALE” Trial, (2011) (4)
Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases (2022) (4)
S1611 MARS: MUTATION-ADJUSTED RISK SCORE FOR ADVANCED SYSTEMIC MASTOCYTOSIS (2019) (4)
Clinical and Immunological Activity of WT1 Peptide Vaccination in Patients with Acute Myeloid Leukemia and Myelodysplasia: Results of a Phase II Trial. (2006) (3)
Dosage effect of zero to three functional LBR-genes in vivo and in vitro (2010) (3)
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma (2010) (3)
The role of zinc protoporphyrin measurement in the differentiation between primary myelofibrosis and essential thrombocythaemia (2011) (3)
Antibody Response to Vaccination with BNT162b2, mRNA-1273, and ChADOx1 in Patients with Myeloid and Lymphoid Neoplasms (2021) (3)
Frequency and Prognostic Impact of NUP98/NSD1 Translocations in Adult AML and MDS Patients (2012) (3)
Clinical “MUTATOME” Of Myelodysplastic Syndrome; Comparison To Primary Acute Myelogenous Leukemia (2013) (3)
Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis (2021) (3)
Inhibition of mast cell tryptase activity. A new therapeutic target against malignancy induced angiogenesis (2008) (3)
“Clinical and Molecular Heterogeneity of Eosinophilia-Associated Myeloproliferative Neoplasms with a Translocation t(5;12)”. (2009) (3)
[Azole resistance in Aspergillus fumigatus - epidemiology and detection in immunocompromised patients in Germany]. (2014) (3)
[Letter to the editor]: whole-genome amplification of sodium bisulfite-converted DNA can substantially impact quantitative methylation analysis using pyrosequencing. (2011) (3)
Genotoxic Bystander Signals from Irradiated Human Mesenchymal Stromal Cells Mainly Localize in the 10–100 kDa Fraction of Conditioned Medium (2021) (3)
An Increased Bone Mineral Density As an Adverse Prognostic Factor in Patients with Systemic Mastocytosis (2019) (3)
Cancer patients and music: (prospective) results from a survey to evaluate potential complementary treatment approaches (2019) (3)
Gene Expression of the Erythroid Regulator Erythroferrone (ERFE) is Highly Deregulated in CD71+ Erythroprogenitor Cells of Patients with Myelodysplastic Syndromes and Demonstrates Prognostic Relevance (2014) (3)
Galactomannan-Based and PCR-Based Assays in Bronchoalveolar Lavage to Diagnose Invasive Aspergillosis: Current Status and Future Prospects (2013) (3)
Urine from current smokers induces centrosome aberrations and spindle defects in vitro in nonmalignant human cell lines. (2010) (3)
BCL6 Is Required for Leukemia-Initiation and Self-Renewal Signaling in Chronic Myeloid Leukemia. (2009) (3)
Comparing the Prognostic Significance of Early Predictors of Survival in Chronic Myeloid Leukemia (CML) Treated with Imatinib - an Analysis of the Randomized CML-Study IV (2014) (3)
An International Multi-Center Study To Define the Application of Microarrays in the Diagnosis and Subclassification of Leukemia (MILE Study): Interim Analysis Based on 1,889 Patients Achieves 95.4% Prediction Accuracy. (2006) (3)
Arsenic Trioxide-Based Therapy Of Relapsed Acute Promyelocytic Leukemia: Updated Results Of The European Registry Of Relapsed APL (PROMYSE) (2013) (3)
Time-Related Interpretation of Molecular Response Levels According to Long Term Overall and Progression-Free Survival of CML Patients on First-Line Imatinib Treatment (2011) (3)
FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study (2021) (3)
Abstract 5119: Frequent splicing pathway mutations and aberrant RNA splicing in myelodysplasia (2012) (3)
Early T-Cell Precursor-ALL in Adult T-ALL. (2009) (2)
Low risk of contrast media induced hypersensitivity reactions in all subtypes of systemic mastocytosis. (2021) (2)
Next Generation RNA Sequencing of Acute Promyelocytic Leukemia (APL) Identifies Novel Long Non Coding RNAs Including New Variants of MIR181A1HG That Are Differentially Expressed during Myeloid Differentiation (2014) (2)
Incidence and Prognostic Impact of Cytogenetics in Combination with Molecular Aberrations in Patients with Systemic Mastocytosis (2016) (2)
Priming with Granulocyte-Colony Stimulating Factor Did Not Improve Outcome in a Randomized Study of Elderly Acute Myeloid Leukemia but Increased Induction Mortality. (2006) (2)
Globular intracytoplasmic inclusions in a patient with chronic lymphocytic leukaemia (2013) (2)
Mast Cell Leukemia: Clinical Heterogeneity, Molecular Aberrations, Treatment Responses, Survival, and Prognostic Factors (2016) (2)
Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes (2021) (2)
Comparative analysis of clonal hematopoiesis of multipotent stem cells in healthy elderly in blood and bone marrow. (2019) (2)
Long-term complete remissions in patients with low-risk myelodysplastic syndromes during combination treatment using all-trans retinoic acid (1998) (2)
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (2022) (2)
Clinical Characteristics and Treatment Allocations in Patients with Myelodysplastic Syndromes and Monosomy 7: Results from an International Multicenter Study Suggest That Hypomethylating Agents Significantly Improve Overall- and AML-Free Survival in Patients Classified As Very High Risk By IPSS-R (2014) (2)
RNA-sequencing of acute promyelocytic leukemia primary blasts reveals novel molecular biomarkers of early death events (2020) (2)
Systemic Mastocytosis with Associated Acute Myeloid Leukemia (SM-AML): a Poor-Risk Multi-Mutated Disease That Follows a Distinct Diagnostic Algorithm and Requires High-Dose Stem Cell-Targeting Therapy (2017) (2)
In Adult Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, The Negative Prognostic Impact Of IKZF1, CDKN2A/B and PAX5 Deletions Is Not Abrogated By Allogeneic Stem Cell Transplantation In First Complete Remission (2013) (2)
High erythroferrone expression in CD71+ erythroid progenitors predicts superior survival in myelodysplastic syndromes (2021) (2)
Co-Expression of BAALC with ERG, TCF4, and CD133 Indicates a Shared Pathway in Acute Myeloid and Lymphoblastic Leukemia. (2005) (2)
Influence of the Insertion Site on Central Venous Catheter Related Complications in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation, High Dose Therapy or Induction Therapy for Acute Leukemia (2015) (2)
Therapy resistance mechanisms in hematological malignancies (2022) (2)
Impact of Balanced or Unbalanced Karyotype At Diagnosis On Prognosis of CML: Long-Term Observation From 1346 Patients of the Randomized CML Study IV (2012) (2)
Characteristics of MDS patients seen at private practices differ significantly from those treated at university hospitals in Germany (2012) (2)
AFM28, a Novel Bispecific Innate Cell Engager (ICE ®), Designed to Selectively Re-Direct NK Cell Lysis to CD123+ Leukemic Cells in Acute Myeloid Leukemia and Myelodysplastic Syndrome (2021) (2)
Safety and Efficacy of the CD95-Ligand Inhibitor APG101 in Transfusion-Dependent Patients with Low Risk MDS: Results from a Phase I Study (2016) (2)
Cancer patients and advance directives (2013) (2)
Impact of Molecular Markers on Response and Resistance in Midostaurin-Treated Patients with Advanced Systemic Mastocytosis (2016) (2)
Phase II trial of vaccination with WT1 peptide, GM-CSF, and KLH in patients with acute myeloid leukemia and myelodysplasia: Final immunological, molecular, and clinical results (2007) (2)
The Fas Ligand Inhibitor APG101 in Transfusion Dependent Patients with Low Risk MDS: Interim Results from a Phase I Study (2014) (2)
Identification of Defects in the Transcriptional Program during Differentiation of CD34+Cells Selected from Patients with Both, Low- and High-Risk Myelodysplastic Syndromes. (2004) (2)
C003 A molecular classification of leukaemia reveals MDS as a disease continuum with non-leukaemia and AML sub groups (2007) (2)
Second Line Therapy with Second Generation TKI After Intolerance to Imatinib Based Treatments Showed High Overall Survival in Contrast to Second Line Therapy After Resistance; Results of the Randomized CML Study IV (2011) (2)
myeloid leukemia tumor suppressor is silenced by hypermethylation in acute Δ The C/EBP (2013) (2)
Front Line Treatment of Elderly Patients with Acute Promyelocytic Leukemia: Long-Term Results of the German AML Cooperative Group (2011) (2)
Inhibitory Effects of Midostaurin and Blu-285 on Myeloid Progenitor Cells Derived from Patients with Multi-Mutated KIT D816V+ Advanced Systemic Mastocytosis (2016) (2)
Separase activity distribution can be a marker of major molecular response and proliferation of CD34+ cells in TKI-treated chronic myeloid leukemia patients (2020) (2)
Therapeutic spectrum in the treatment of myelodysplastic syndromes (2004) (2)
Humanized 3D scaffold xenotransplantation models for Myelodysplastic Syndromes (2021) (1)
296 Telomere shortening is associated with AML progression in patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide (2011) (1)
Health-Related Quality of Life Impairment in Patients with Chronic Myeloid Leukemia: Results of a German Cross-Sectional Study of Patients Registered in Prospective, Controlled Clinical Trials (2015) (1)
Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts Short title: GENETIC ANOMALIES IN MSCs OF MDS/AML PATIENTS (2011) (1)
ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes (2022) (1)
Transcriptional Down-Regulation of the Wnt Antagonist SFRP1 Is Associated to Promoter Hypermethylation as Detected by Pyrosequencing in Hematopoietic Cells of Patients with Different Risk-Types of MDS, ALL and AML. (2009) (1)
Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment (2015) (1)
Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA (2017) (1)
Elderly CML Patients On Early Applied High Dose Imatinib Achieve Molecular Remissions As Fast As Younger Patients In Contrast To Patients On Standard Dose Imatinib: A Subanalysis Of The German CML-Study IV (2013) (1)
Erratum: Cumulative radiation exposure from imaging procedures and associated lifetime cancer risk for patients with lymphoma (2017) (1)
High expression of the transcription factor ERG predicts unfavorable outcome in acute T-lymphoblastic leukemia (T-ALL) in adults. (2006) (1)
Identification of ERG Specific Target Genes by Genome-Wide Screening in T-Lymphoblastic Leukemia (2008) (1)
Myelodysplastic Syndromes: Molecular mechanisms and gene expression patterns in myelodysplastic syndromes (2005) (1)
Defining Therapy Goals for Major Molecular Remission in Chronic Myeloid Leukemia: Results of the Randomized CML-Study IV (2014) (1)
Priming with Granulocyte Colony-Stimulating Factor (G-CSF) Has No Impact on Treatment Outcome but Impairs Mobilization of Peripheral Blood Stem Cells (PBSC) in Elderly Patients with Acute Myeloid Leukemia: Results of a Randomized Oligocenter Trial. (2004) (1)
In Vivo Drug-Response in Patients with Leukemic Non-Hodgkin’s Lymphomas Is Predicted by In Vitro Chemosensitivity Testing and Gene Expression Profiling. (2004) (1)
An International Multi-Center Study To Define the Application of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia (MILE Study): Analysis of Completed Stage I with 2030 Patients Achieved a 95.4% Accuracy. (2007) (1)
Mechanism of action of demethylating and immune modulatory agents--discussion. (2011) (1)
BCL6-Mediated Survival Signaling Promotes Drug-Resistance in BCRABL1- Driven Acute Lymphoblastic Leukemia (2008) (1)
Pre-B Cell Receptor Signaling Distinguishes E2A-PBX1 From Other Subtypes of Acute Lymphoblastic Leukemia (2010) (1)
leukemia identifies heterogeneous secondary genomic alterations SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid (2011) (1)
Novel Role of Ras-GTPase Activating Protein SH3 Domain-Binding ProteinG3BP in Adhesion and Migration of 32D Myeloid Progenitor Cells (2012) (1)
A New Prognostic Score for Advanced Systemic Mastocytosis Based on Clinical and Genetic Characteristics of 210 Consecutive Patients (2018) (1)
The Pax5 Fusion Product Pax5-C20orf112 Causes Downregulation of Pre-B Cell Receptor Genes and Induces Differential Proliferation Patterns in B-Lymphoblastic Cell Lines. (2009) (1)
Inactivation of Pre-B Cell Receptor-Mediated Tumor Suppression by Aberrant Splicing in Ph+ Acute Lymphoblastic Leukemia. (2009) (1)
Microarray Classification of Myelodysplastic Syndrome (MDS) Identifies Subgroups with Distinct Clinical Outcomes. (2007) (1)
Diagnostic Value of sST2, VCAM-1, and Adiponectin in Patients with Breast Cancer to Predict Anti-Tumour Treatment-Related Cardiac Events: A Pilot Study (2022) (1)
Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study (2018) (1)
Proteins Marking the Sequence of Genotoxic Signaling from Irradiated Mesenchymal Stromal Cells to CD34+ Cells (2021) (1)
MDR1 Gene Expression Predicts Response and Progression-Free Survival Of Ph+ CML Patients On Second-Line Nilotinib Therapy After Imatinib Failure - 4-Year Follow-Up (2013) (1)
Distinct Characteristics of e13a2 versus e14a2 BCR-ABL Chronic Myeloid Leukemia under Upfront Treatment with Imatinib – an Analysis of the German CML Study IV, (2011) (1)
Mechanisms of Pre-B Cell Receptor-Inactivation In Acute Lymphoblastic Leukemia (2010) (1)
WT1) peptide vaccination in patients with AML and MDS A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (2009) (1)
Genomic CDKN 2 A / 2 B deletions in adult Ph + ALL are adverse despite allogeneic stem cell transplantation (2018) (1)
Pretreatment Expression Levels of MDR1 and OCT-1 Predict Response to First Line Imatinib Treatment In Chronic Phase CML Patients (2010) (1)
Aspergillus Specific PCR and Galactomannan of Bronchoalveolar Lavage Are Superior to Concomitant Same-Day Testing of Concurrent Blood Samples in Immunocompromised Hematological Patients with Suspected Invasive Aspergillosis (2015) (1)
Aberrant Splicing of the SLP65 SH2 Domain Enables Pre-B Cell Transformation and Compromises the Leukemia-Suppressive Function of the Pre-B Cell Receptor (2008) (1)
Hodgkin's lymphoma in a patient with cystic fibrosis: a clinical challenge (2013) (1)
Acute myeloid leukemia KIT D 816 mutated / CBF-negative acute myeloid leukemia : a poor-risk subtype associated with systemic mastocytosis (2019) (1)
Sequential Combination of Azacitidine and Lenalidomide Can Target the TP53 -Mutated Clone in Del(5q) Higher-Risk Myelodysplastic Syndromes (2012) (1)
Differential Effects of Sound Intervention and Rest on Cardiovascular Parameters in Cancer Patients: A Randomized Cross-over Trial (2021) (1)
Impact of ABCG2, OCT1 and ABCB1 (MDR1) N Treatment Free Remission in an Euroski Subtrial (2017) (1)
Gene Expression Profiling Identifies IGFBP7 as a BAALC Co-Expressed Gene with a Functional Role in Acute Leukemia. (2009) (1)
mutated / CBF-negative acute myeloid leukemia (2019) (1)
Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study (2013) (1)
Therapy With Demethylating Agents Significantly Improves Overall- and AML-Free Survival In Patients With MDS Classified As High-Risk By IPSS Or Very High Risk By IPSS-R and Partial Or Total Monosomy 7-Results From a German Multicenter Study (2013) (1)
Modulation of vincristine cytotoxicity by dexverapamil in sensitive and resistant HL-60 cell lines as a function of extracellular protein binding. (1998) (1)
Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile (2020) (1)
Detection of Highly Clonal CD34 + , Mononuclear Bone Marrow and Peripheral Blood Cells From Patients with Myelodysplastic Syndrome and Age Related Increase of Clonal Hematopoiesis In Healthy Subjects Using a Novel Transcriptional Pyrosequencing Based Clonality Assay (2010) (1)
Low Expression of IL-15 in Adult B-Lineage Acute Lymphoblastic Leukemia Is Associated with Central Nervous System Involvement at Initial Presentation. (2007) (1)
174 Intensive chemotherapy (idarubicin, ARA-C, VP-16) combined with G-CSF-priming yields high remission rates in patients with advanced MDS and high-risk AML (1997) (1)
The Pre-B Cell Receptor Suppresses Leukemogenesis by Censoring MYC Expression. (2008) (1)
CD34+ FISH As a New Method for Molecular-Cytogenetic Diagnostic From Peripheral Blood in MDS: Update of the Multicenter German Prospective Diagnostic Study (2012) (1)
Multidrug-Resistant Bacterial Pathogens in Allogeneic Hematopoietic Cell Transplantation - a Retrospective Single Center Analysis (2014) (1)
Expression of DNMT Isoforms Is Differentially Associated with Aberrant Promotor Methylation in MDS Hematopoietic Progenitor Cells during Lineage Specific Differentiation. (2006) (1)
Inhibition of Phosphotyrosine Phosphatase-1B (PTP1B) Induces Resistance to the ABL Kinase Inhibitor Imatinib Mesylate (Gleevec®) in BCR-ABL Positive Leukemic Cells. (2004) (0)
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (2022) (0)
Identification of Epigenetically Silenced Tumor Suppressor Genes in Myeloid Disorders Leads to the Identification of α-Catenin as a Target Gene in 5q- Syndrome. (2004) (0)
Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies (2023) (0)
High Density SNP Array Analysis of Tyrosine Kinase Inhibitor (TKI) Resistant Chronic Myeloid Leukemia (CML) Shows Secondary Genomic Alterations (2008) (0)
Molecular predictors for the response to nilotinib treatment after acquired imatinib failure in ph+ chronic myeloid leukemia (2010) (0)
Genotoxic bystander signals from irradiated human mesenchymal stromal cells mainly localize in the 10 – 100 kDa fraction of conditioned medium (2020) (0)
Inter-Modality Variance of Blast Quantification in Patients with Myelodysplastic Syndrome (MDS) and Its Impact on Risk Stratification and Overall Survival (2022) (0)
Thrombopoietic Growth Factors — Managing Thrombocytopenia (2000) (0)
Erythroferrone (ERFE) Is Selectively Expressed in Human CD71+ Erythroprogenitor Cells and Deregulated Overexpression Is Associated with a Favorable Outcome in Low Risk Myelodysplastic Syndrome (MDS) (2015) (0)
Hodgkin's lymphoma in a patient with cystic fibrosis (2013) (0)
Abstract 5565: Histone Deacetylase 5 Regulates Angiogenic Growth Factors And Guidance Molecules And Represses Angiogenesis (2008) (0)
Differentiation therapy for myelodysplastic syndrome. (2002) (0)
[Granulocyte function in myelodysplastic syndrome before and after low-dose cytarabine therapy]. (1993) (0)
Transcriptomic Changes upon Ageing of Bone Marrow Derived Mesenchymal Stromal Cells and Onset of MDS (2017) (0)
Analysis of Immunological and Clinical Response Kinetics to WT1 Peptide Vaccine in Patients with AML and MDS: Need for Supplementation of IWG Response Criteria?. (2007) (0)
Detection of Differential Mitotic Cell Ages in Bone Marrow CD34+ Cells Selected from Patients with Myelodysplastic Syndrome and Acute Leukemia by Pyrosequencing Analysis of An Epigenetic Molecular Clock DNA Signature (2008) (0)
ERG Overexpression Induces Cell Adhesion Mediated Drug Resistance in Acute Leukemia (2011) (0)
KIT D816 Mutated / CBF-Negative Acute Myeloid Leukemia (AML): A New Poor-Risk Subtype Associated with Systemic Mastocytosis (SM-AML) (2018) (0)
Anti-Leukemic Efficacy of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies (2019) (0)
C/EBPδ Modulates Cell Growth, Differentiation and Apoptosis of Myeloid Leukemia, Prostate and Breast Cancer Cells. (2004) (0)
Erratum to: High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia (2014) (0)
Hybrid eosinophilic-basophilic acute myeloid leukaemia diagnosed by electron microscopy (2007) (0)
Molecular Alterations in Bone Marrow Mesenchymal Stroma Cells of AML Patients (2014) (0)
Significant Engraftment of Immature Hematopoietic Cells From Patients with Low Risk Myelodysplastic Syndromes (MDS) in Immunodeficient Mice (2012) (0)
Inhibition of Lysyl Oxidases Synergizes with 5-Azacytidine to Restore Erythropoiesis in Myeloid Neoplasms (2022) (0)
Molecular characteristics of FLT3 mut ETP-ALL versus FLT3 wt ETP-ALL patients. (2013) (0)
Quantitative Analysis of Patient-Specific Lesions in Primary and Xenografted Myelodysplastic Syndromes Reveals Complex Hierarchies and Subclonal Diversity That Evolve during Disease Progression (2014) (0)
The New CD95 Ligand Inhibitor APG101 Leads To Decreased Apoptosis and Improved Erythroid Differentiation In Primary CD34+ Cells From Patients With Low Risk Myelodysplastic Syndrome (MDS) (2013) (0)
[Acute Promyelocytic Leukemia - A Rare, Life-Threatening Disease with High Healing Chance]. (2018) (0)
Erratum: Cumulative radiation exposure from imaging procedures and associated lifetime cancer risk for patients with lymphoma. (2017) (0)
Whole Genome Sequencing of Azole-Resistant Aspergillus Fumigatus Strains from Hematopoietic Stem Cell Recipients Identifies Candidate Molecular Targets Potentially Implicated in Novel Resistance Mediating Mechanisms - First Results (2015) (0)
Comparison of Four Different Humanized Hematopoietic Niche Xenotransplantation Methods to Engraft Myelodysplastic Syndromes (MDS) (2019) (0)
Achievement Of a MR5.0 Within the Randomized CML-Study IV: Feasibility, Differences Between Treatment Arms, and Prognostic Implications (2013) (0)
Frequency of the observed hematological changes in total blood cell count according to five trials with more than 30 patients (2009) (0)
γH2AX Foci Increase Across the Spectrum from Myelodysplastic Syndromes to Acute Myeloid Leukemias and Co-Localize with 53BP1 in Specific Patterns in the Context of an Impaired DNA Damage Response (2016) (0)
Analysis Of Micro-RNA-142 Mutations In a Cohort Of 944 Patients With MDS and AML (2013) (0)
The Impact Of Balanced and Unbalanced Karyotypes On Prognosis Of CML: From Chronic Phase To Blast Crisis (2013) (0)
Prediction of response and resistance to treatment by gene expression profiling (2001) (0)
68 ASXL1 is frequently mutated and associated with a negative prognosis in MDS (2011) (0)
Identification of the PML-RARα Associated DNA Methylome Using Reduced Representation Bisulfite Sequencing in Primary Patient Samples (2011) (0)
Mesenchymal Stromal Cells (MSCs) from Myelodysplastic Syndromes (MDS) Are Not Clonally Mutated I n Vivo (2021) (0)
Pre-B Cell Receptor Signaling Prevents Leukemic Transformation by BCR-ABL1 . (2007) (0)
Selective Suppression of the DNA Damage Response in Acute Myeloid Leukemia Versus Myelodysplastic Syndrome. (2008) (0)
High WT1 Expression Is Associated with a Shorter Time to Complete Remission After ATRA Based Induction Therapy In Acute Promyelocytic Leukemia (2010) (0)
Irradiated mesenchymal stromal cells induce genetic instability in human CD34+ cells (2020) (0)
Comprehensive Profiling of Somatic Mutations Which Define Primary Disease and Relapse in Various Acute Leukemia Subtypes (2012) (0)
Preclinical Assessment of Alvocidib in Combination with 5-Azacytidine in High-Risk Myelodysplastic Syndromes (2021) (0)
Functional imaging with dual-energy computed tomography for supplementary non-invasive assessment of mast cell burden in systemic mastocytosis (2022) (0)
PAX5-Mediated Lineage Conversion and Expression of AID Accelerates Clonal Evolution and Initiates Darwinian Selection of BCR-ABL1-Mutants in Chronic Myeloid Leukemia. (2007) (0)
254 Array based methylation analysis identifies DBC1, CDH1, DCC and WT1 as differentially methylated and prognostically relevant candidate genes in MDS (2011) (0)
Identification of Highly Clonal Cells in CD34+ and Unselected Bone Marrow Samples From Patients with Myelodysplastic Syndrome Using a Sensitive Quantitative PCR Approach. (2009) (0)
Chemotherapy with Idarubicin, Ara-C,VP-16, Amsacrine, Followed by G-CSF and Maintenance Immunotherapy with Interleukin-2 for Patients with High-Risk Acute Myeloid leukemia: a 3-Years Follow-Up (1998) (0)
The 3-month velocity of BCR-ABL decline: a tool for predicting deep molecular response in CML patients (2016) (0)
Different Impact of Expression Levels of IGFBP2 and IGFBP7 on Survival and Relapse Rate in Acute Promyelocytic Leukemia (2015) (0)
Prediction of Response to Treatment with Lenalidomide in Patients with Non-Del 5q Myelodysplastic Syndrome by Gene Expression Profiling Remains Difficult. (2009) (0)
MR-Bildgebung bei akuter abdomineller Graft versus Host Disease (2013) (0)
189 Infectious complications after intensive remission induction in advanced myelodysplastic syndromes and de novo acute myeloid leukemia (1997) (0)
Therapy of Advanced MDS, AML Evolving from MDS, or Secondary AML with Idarubicin Ara-C, VP-16, Followed by G-CSF-Priming Exhibits High Remission Rate (1998) (0)
R-Loops-Induced ATR Signaling As a Potential Therapeutic Target in Myelodysplastic Syndrome (2019) (0)
Genome Wide DNA Methylation Analysis Reveals Significant Differences Between Blasts of Patients with Acute Promyelocytic Leukemia and CD34 + -Hematopoietic Stem Cells of Healthy Individuals (2011) (0)
150 Treatment of low-risk MDS: Combination of hematopoietic growth factors and biological response modifiers (1997) (0)
Erk and Stat5 Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia (2014) (0)
Incidence and prognostic impact of cytogenetic aberrations in systemic mastocytosis (2016) (0)
Rare mutations of the PIK3CA gene in a number of cancer types and discovery of a PIK3CA pseudogene (2005) (0)
P-239 Telomere length of granulocytes significantly increases during the first six months of lenalidomide treatment in patients with isolated 5q- syndrome (2013) (0)
Aggressive Systemic Mastocytosis Is Associated with a High Kit D816V Allele Burden in Peripheral Blood. (2009) (0)
P068 Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome (2009) (0)
O-023 Did the prognosis of MDS patients improve during the last 30 years? (2013) (0)
119 UPDATE ON THE MULTICENTER MDS BIOREGISTRY PROJECT OF THE “KREBSHILFE-VERBUNDFORSCHUNGSPROJEKT MDS” OF THE GERMAN MDS STUDY GROUP (2015) (0)
84 In vitro effect of c-mpl-ligand on CD34 positive cells isolated from patients with chronic myelodysplastic syndromes (MDS) (1997) (0)
Differential Expression of ERG Isoforms in Acute Myeloid and T-Lymphoblastic Leukemia Is Regulated by DNA-Methylation. (2007) (0)
Reply to Aloyz et al (2005) (0)
Significant Down-Regulation of BAALC during Lineage Specific Hematopoietic Differentiation. (2004) (0)
A Role of Autotaxin in Non-Mutational Resistance in Imatinib-Resistant Acute Lymphoblastic Leukemia (ALL) Cell Line SupB15RT. (2007) (0)
Malignancy: Current Clinical Practice: Current Therapeutic Options in Myelodysplastic Syndromes. (1999) (0)
acute myeloid leukemia: results of a randomized phase III trial immunotherapy with histamine dihydrochloride and interleukin-2 in Improved leukemia-free survival after post-consolidation (2013) (0)
Inferior Outcome in Patients with Acute Promyelocytic Leukemia and High Expression of the Ets Related Gene : Role in Leukemogenesis and Potential Implications for Future Therapeutic Approaches?, (2011) (0)
Mesenchimal Stroma Cells From Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia Show Distinct Cytogenetic and DNA-Mutation Data as Compared with Bone Marrow Leukemic Blasts. (2009) (0)
Detailed Genome-Wide DNA-Mapping of CD34+ Cells Purified from Patients with MDS Using High-Resolution SNP Arrays Identifies Significant Regions of Genomic Alterations. (2006) (0)
The EUROSKI biomarker study: Analyzing the mechanisms of treatment-free remission in chronic myeloid leukemia (2017) (0)
P-252 Routes of clonal evolution into complex karyotypes in myelodysplastic syndrome patients with del(5q) (2013) (0)
Clinical characteristics and treatment with ruxolitinib in patients with PCM1-JAK2 and BCR-JAK2 positive myeloid/lymphoid neoplasms with eosinophilia (2017) (0)
High Expression of IL-15 Correlates with Disease Recurrence of Adult B-Lineage Acute Lymphoblastic Leukemia (2008) (0)
Reply to Aloyz et al (2005) (0)
The KIT D816V Allele Burden in Systemic Mastocytosis Is Strongly Associated with Disease Subtype. (2012) (0)
Identification of novel epigenetically silenced tumor suppressor genes in myeloid disorders (2004) (0)
Evidence for Recombinant GRP78, CALR, PDIA3 and GPI as Mediators of Genetic Instability in Human CD34+ Cells (2022) (0)
Investigation Of Fresh Tissue and Effusion Samples From Immunocompromised Hematologic Patients Suspected For Invasive Fungal Infection With An Aspergillus-specific PCR Is a Promising Tool For Identifying Invasive Aspergillosis (2013) (0)
P771: PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY (2022) (0)
CML Study IV of CML: long-term observation of 1151 patients from the randomized Impact of additional cytogenetic aberrations at diagnosis on prognosis (2012) (0)
Analysis of Chromosomal Aberrations and DNA Mutations in Bone Marrow Mesenchymal Stroma Cells from Patients with Myelodysplastic Syndrome Amd Acute Myeloid Leukemia (2008) (0)
KIT D816V and JAK2 V617F Point Mutations Are Recurrently Found In Suspected Hypereosinophilic Syndrome (2010) (0)
Overexpression of BAALC Indicates Drug Resistance and Inferior Survival in Adult B-Precursor Acute Lymphoblastic Leukemia. (2009) (0)
A Risk Score Integrating BAALC, ERG and WT1 Expression Can Be Used To Improve Risk Stratification In Acute Promyelocytic Leukemia (2013) (0)
RNA Sequencing of Bone Marrow Derived Mesenchymal Stromal Cells (MSCs) of Healthy Young, Healthy Old and Patients with Myelodysplastic Syndrome (MDS) Reveals Transcriptomic Changes upon Aging of the Niche and Onset of MDS (2016) (0)
Activity Of Single Agent Temsirolimus and Associated Impact On Bone Marrow Vascularization and T-Cell Composition In Patients With Myelodysplastic Syndromes – Result Of The Prospective Temds Trial Of The German MDS-SG (2013) (0)
An International Multi-Center Microarray Study for the Molecular Classification of Leukemia Identifies Novel Sub-Groupings in MDS Overlapping with AML. (2006) (0)
c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemia (2016) (0)
Abstract 4602: Recurrent pathway mutations of multiple components of cohesin complex in myeloid neoplasms. (2013) (0)
A new aberrantly spliced BCR‐ABL1 transcript variant (e13a1) identified in routine monitoring using different quantitative reverse transcription polymerase chain reaction techniques in a patient with chronic myeloid leukemia (2022) (0)
Statistical biases due to anonymization evaluated in an open clinical dataset from COVID-19 patients (2022) (0)
227 CD71+ ERYTHROPROGENITOR CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROMES DISPLAY DISTURBED REGULATION OF ERYTHROPOIESIS STIMULATING ERYTHROFERRONE (ERFE) IN ASSOCIATION WITH DIFFERENTIAL PROGNOSTIC SIGNIFICANCE (2015) (0)
Cytogenetic and Molecular Genetic Aberrations in Bone Marrow Mesenchymal Stroma Cells from Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. (2007) (0)
Clonal hierarchies and dynamic evolution in Myelodysplastic Syndromes (MDS) upon therapy (2016) (0)
Direct Comparison of NSG and NBSGW Mice for MDS Patient-Derived Xenograft Models (2022) (0)
[Antifungal medication: new substances, new experiences]. (2016) (0)
Mutations in Specific NOTCH1 Domains Convey a Distinct Phenotype in Adult Acute T-Lymphoblastic Leukemia. (2007) (0)
Rare Mutations of the PIK3CA Gene in Hematologic Malignancies. (2004) (0)
Integrated Analysis of Epigenetic and Genetic Changes During MDS Progression Reveals the Tight Association of Epigenetic Changes with Genetic Selection (2017) (0)
High Density SNP Array Analysis of Acute Promyelocytic Leukemia (APL) Detects New Common Genomic Copy Number Alterations as Possible Cooperating Lesions (2010) (0)
Promotor Demethylation as a Mechanism of HOX11 Activation in Adult T-ALL?. (2006) (0)
MDS-Derived Stromal Cells Exhibit Altered Gene Expression and Support The Engraftment Of lin-CD34+CD38- Disease-Initiating Stem Cells In a Xenograft Model Of Lower Risk MDS (2013) (0)
119 2011-update and overview of data in the German-Austrian-Suisse MDS registry (D-A-CH MDS registry) (2011) (0)
Array-Based Integrative Analysis Of Epigenomic and Transcriptomic Alterations In CD71+ Bone Marrow Erythroprogenitor Cells From Patients With Myelodysplastic Syndromes (2013) (0)
9-cis-retinoic acid treatment for myelodysplasia [Abstract] (1998) (0)
Identification of a new subgroup of adult acute T-lymphoblastic leukemia (T-ALL) with a very favorable outcome using low ERG and BAALC expression (2007) (0)
Pentostatin for First-Line Salvage Therapy of Steroid-Refractory Intestinal Acute Graft-Versus-Host Disease; a Dual Center Retrospective Analysis (2010) (0)
Wilms Tumor 1 Gene Mutations in Adult Acute T-Lymphoblastic Leukemia (2008) (0)
257 Inactivation of ICSBP by promoter methylation is likely involved in progressive leukemogenesis (2011) (0)
Identification of potential molecular candidate lesions by molecular analysis of desmoid tumors with qrt-PCR and high-density SNP arrays. (2011) (0)
O-013 Mesenchymal stromal cells support significant engraftment of low-risk myelodysplastic syndromes (MDS) in a murine xenograft model (2013) (0)
Protein Phosphatase 2A regulatory subunit Balpha controls vascular development by regulating endothelial cell adhesion dynamics (2011) (0)
The Identification of ERG Related Pathways Pinpoints to Mechanisms Implicated in the Inferior Outcome of Acute T-Lymphoblastic Leukemia (T-ALL) with High ERG Expression. (2006) (0)
The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug-Resistance in Chronic Myeloid Leukemia. (2009) (0)
Survivin Isoforms and HSP90 Are Downregulated in Erythropoiesis during Lineage Specific Differentiation of MDS Hematopoietic Progenitor Cells. (2006) (0)
Genomic landscape in KIT D816V+ advanced systemic mastocytosis (2015) (0)
Technique of microarrays: microarray platforms (2001) (0)
Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomid: Results from the German Prospective Le-Mon-5 Trial (2014) (0)
Effect of PEG-rHu MGDF in the induction treatment of acute myeloid leukemia (1997) (0)
Validation of a Molecular Risk Score for Prognosis of Patients with Acute Promyelocytic Leukemia (2016) (0)
Identification of Recurrent Submicroscopic Deletions of chromosome1q31.3 As Possible Molecular Prognostic Markers in Acute Promyelocytic Leukemia (APL) (2011) (0)
Mechanism of action of demethylating and immune modulatory agents--introduction. (2011) (0)
Vorspann (1997) (0)
Identification of MDS-Specific and Methylation Associated Downregulation of Survivine and WT1 in Highly Purified Hematopoietic Progenitor Cells during In Vitro Lineage Specific Differentiation. (2005) (0)
Identification of Characteristic Findings by Abdominal Magnetic Resonance Imaging in Acute Intestinal Graft Versus Host Disease (2012) (0)
Safety and efficacy of the CD95-ligand inhibitor APG101 in transfusion-dependent patients with low risk MDS: Interim results from a phase I study. (2016) (0)
Regulated Kinases p 44 Kinase p 38 and by the Extracellular Production by the Stress γ and Mediates IFN-Cell Line 92 , Augments Cytotoxic Activity , IL-18 Activates STAT 3 in the Natural Killer (2000) (0)
P-316 TP53 mutations in patients with myelodysplastic syndrome and isolated deletion (5q) treated with lenalidomide: Results from the German Le-Mon-5 trial (2013) (0)
Mechanism of action of demethylating and immune modulatory agents--conclusion. (2011) (0)
Labile Plasma Iron Predicts for Survival in Patients Undergoing Allogeneic Stemcell-Transplantation – Results from the Prospective Multicenter German-Austrian Allive Trial (2017) (0)
Clinical Characteristics and Treatment with Various Tyrosine Kinase Inhibitors in Patients with ETV6-ABL1 positive Eosinophilia-Associated Myeloproliferative Neoplasms (2016) (0)
In Acute Promyelocytic Leukemia (APL) Low BAALC Gene Expression Identifies a Group of Patients with Favorable Outcome in Overall Survival and Relapse Free Survival (2011) (0)
Exome Sequencing Identifies Recurring DNMT3A Mutations in Adult ETP-ALL (2012) (0)
The Cytogenetic Profile In Lymphoid and Myeloid CML Blast Crisis (2013) (0)
Molecular Changes in Myelodysplastic Syndrome (2011) (0)
Abstract 6257: Mutations in the ASXL1 and ZRSR2 genes are associated with the response to the combination of alvocidib and 5-azacytidine in higher-risk myelodysplastic syndromes (2022) (0)
Genome Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome and Isolated Deletion (5q) Reveals Characteristic Methylation Profiles in Low and Intermediate-1 Risk Groups (2012) (0)
Mast cell leukemia: clinical heterogeneity, molecular aberrations and prognostic factors (2016) (0)
Clinical Phenotype of Myeloproliferative Neoplasms with Activating CBL-mutations Resembles Chronic Myelomonocytic Leukemia. (2009) (0)
An Optimized Risk Stratification Model in Acute Promyelocytic Leukemia Identifies Patients with an Exceptionally Good Prognosis Regarding the Incidence of Relapse (2014) (0)
Effects of a Sound Intervention on Physical and Emotional Well-Being in Patients with Cancer: A Prospective Randomized Trial (2023) (0)
Mutational Complexity Is Related To Disease Severity In Systemic Mastocytosis (2013) (0)
Skewed X-Inactivation Patterns in Aging Healthy and Myelodysplastic Hematopoiesis Determined By a Novel Transcriptional Clonality Assay (0)
New Aspects of the Treatment of Patients with Low-Risk Myelodysplastic Syndromes (2000) (0)
Abstract 925: Whole exome analysis of myelodysplastic syndromes (2011) (0)
Comparison of RNA-Based Versus DNA-Based Quantitative KIT D816V Mutation Analysis Reveals Significant Disparity in Patients with Advanced Systemic Mastocytosis (2019) (0)
Identification of Putative New Tumor Suppressor Genes in Highly Purified CD34+ Bone Marrow Cells from Patients with Myelodysplastic Syndromes. (2004) (0)
Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI) (2022) (0)
Placebo Controlled Functional Analysis of Eltrombopag in a Preclinical Xenograft Model of Myelodysplastic Syndromes (MDS) (2018) (0)
Rearrangement Gene IGL Deletion , and IGK Rearrangement , Gene IGK Sequence of Primary and Secondary in Human Leukemia Cells Reveals a Coordinated Tracing the Pre-B to Immature B Cell Transition (2004) (0)
Topic: AS08-Treatment/AS08e-New developments - Preclinical studies (2021) (0)
The Impact of Colonization with Multidrug-Resistant Bacterial Pathogens (MRP) in Allogeneic Hematopoietic Cell Transplantation - Clearance of the MRP Is Pivotal for Survival (2016) (0)
Cytogenetic classification according to IPSS/-R is possible from peripheral blood in patients with Myelodysplastic Syndromes (2016) (0)
Molecular Characterization Of The Anti-Leukemic Effects Of Single Agent Eltrombopag (2013) (0)
[Current treatment options for myelodysplastic syndromes]. (2010) (0)
Molecular Targets in Myelodysplastic Syndromes (2007) (0)
Genome Wide DNA Methylation Analysis Identifies a Characteristic Methylation Profile for Patients with Acute Promyelocytic Leukemia and FLT3-Internal Tandem Duplication (2012) (0)
GATA and BCLxl Downregulation in Erythropoiesis during In Vitro Lineage Specific Differentiation of MDS Hematopoietic Progenitor Cells Is Not Induced by Activated Notch Pathway. (2007) (0)
Next Generation Sequencing-Based Molecular Dissection Of Lineage-Specific Mutational Hierarchies In Oligoclonal Primary and Xenografted Myelodysplasia (2013) (0)
Functional imaging with dual-energy computed tomography for supplementary non-invasive assessment of mast cell burden in systemic mastocytosis (2022) (0)
Lymphoid Blast Crisis Transformation and Development of Drug- Resistance in Chronic Myeloid Leukemia Are Driven by Aberrant Somatic Hypermutation (2008) (0)
Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial (2018) (0)
TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial (2013) (0)
WHERE SCIENCE MEETS CLINICAL PRACTICE (2014) (0)
347 Successful treatment of transfusional iron overload in MDS patients with deferasirox as indicated by Liver-MRI: A German, multi-center trial (2011) (0)
Inhibition of Phosphotyrosine Phosphatase 1 BCauses Resistance in BCR-ABL-PositiveLeukemiaCells totheABLKinase InhibitorSTI 571 (2006) (0)
Adverse Cardiovascular Effects of Anti-tumor Therapies in Patients With Breast Cancer: A Single-center Cross-sectional Analysis (2022) (0)
156 a Novel Pcr-Based Assay for Targeted Quantification of Del(5q) in Myelodysplastic Syndromes (2015) (0)
Absolute BCR-ABL Transcript Levels At 3 Months but Not At Diagnosis Predict Survival of Chronic Myeloid Leukemia (CML) Patients On Imatinib Therapy (2012) (0)
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q) (2021) (0)
In Silico Pan-Cancer Analysis Reveals Prognostic Role of the Erythroferrone (ERFE) Gene in Human Malignancies (2023) (0)
P-114 SETBP1 mutations in MDS and sAML (2013) (0)
Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis. (2022) (0)
A Two-Fold Rise of BCR-ABL Transcript Levels Advises BCR-ABL Mutation Analysis in Imatinib-Treated Chronic Myeloid Leukemia (CML) - an Analysis of the Randomized CML-Study IV (2014) (0)
Development of a DNA-Based Targeted Assay Suitable for Accurate Quantification of Chromosomal Deletions in Myelodysplastic Syndromes with Deletion (5q) and Other Clonal Diseases (2014) (0)
Epigenetic Dysregulation of GATA1 but Not Downstream Notch Effectors is Involved in MDS Dyserythropoiesis. (2008) (0)
Consequent Iron Chelation Therapy in Patients with Low Risk Myelodysplastic Syndrome Leads to up-Regulation of .CXCL12, JAK2 and HSF2: Possible Link Between Iron Chelation and Improvement of Erythropoiesis. (2009) (0)
Mesenchymal and MDS stem cells shape an interactive disease unit in the bone marrow (2014) (0)
Cytogenetic monitoring from peripheral blood in patients with myelodysplastic syndrome: First results from the German LEMON-5 trial (2016) (0)
Gene expression profiling of differentiating hematopoietic stem cells identifies transcriptional dysregulation in haematological malignancies (2013) (0)
The Role of MSI2 Expression Levels on Outcome of MDS and AML Patients (2011) (0)
Gene Rearrangement IGL Deletion, and IGK Gene Rearrangement, IGK Secondary a Coordinated Sequence of Primary and Reveals Transition in Human Leukemia Cells Tracing the Pre-B to Immature B Cell (0)
Gene therapy for chronic granulomatous disease: Ups and downs (2009) (0)
84: Mesenchymal and MDS stem cells shape an interactive disease unit in the bone marrow (2014) (0)
implicated in myeloid leukemia Transcription profiling of C / EBP targets identifies Per 2 as a gene (2005) (0)
Analysis of end-of-life treatment and physician perceptions at a university hospital in Germany (2021) (0)
65 MYELODYSPLASTIC SYNDROMES ARE CHARACTERIZED BY RECURRENT PATTERNS IN PATIENT-INDIVIDUAL MUTATIONAL HIERARCHIES THAT ARE SUBJECT TO HIGHLY DYNAMIC SUBCLONAL EVOLUTION DURING THERAPY AND DISEASE PROGRESSION (2015) (0)
Telomere Length Of Granulocytes Significantly Increases During The First Six Months Of Lenalidomide Treatment In Patients With Isolated 5q- Syndrome (2013) (0)
A Multicenter Retrospective Analysis on Pentostatin As Salvage Therapy of Severe Steroid Refractory Intestinal Acute Graft Versus Host Disease (2011) (0)
9.1 Supportive Therapie myelodysplastischer Syndrome (2012) (0)
Diagnostic Performance of Contrast Enhanced Pulmonary Computed Tomography Angiography for the Detection of Angioinvasive Pulmonary Aspergillosis in Immunocompromised Patients (2017) (0)
The Novel Bispecific Innate Cell Engager (ICE®) AFM28 Efficiently Directs Allogeneic NK Cells to CD123+ Leukemic Stem- and Progenitor Cells in AML (2022) (0)
Megakaryocytic growth in patients with refractory anemia is suppressed by treatment with interferon alpha (1999) (0)
The predictive impact of MDR1 expression and pre-tumor burden on molecular, cytogenetic and clinical outcome of CML patients on nilotinib therapy after imatinib failure (2010) (0)
Abstract 559: Elevated Level of sCD40L During Acute Coronary Syndrome Leads to Systemic MIP-2 Release (2008) (0)
P069 Genome-wide DNA-mapping of CD34+ cells from MDS patients with 500K SNP arrays identifies significant regions of genomic alterations (2007) (0)
Splenomegaly and elevated alkaline phosphatase are strong and independent adverse prognostic markers in patients with systemic mastocytosis (2016) (0)
The Pattern Of Cytogenetic Aberrations In CML BC Stratified For Treatment (2013) (0)
Critical Evaluation of Diverse Clinical, Laboratory, Radiological and Histological Parameters Indicating Gastrointestinal Involvement for Diagnosis of Indolent and Aggressive Systemic Mastocytosis (2011) (0)
Early Thymic Progenitor Leukemia (ETP-ALL) in Adults: A Distinct Molecular Entity, (2011) (0)
Erythroferrone (ERFE) and Growth Differentiation Factor 15 (GDF15) Are Overexpressed in Erythroprogenitor Cells of MDS Patients and Associated with Survival (2017) (0)
Accumulation of DNA Damage and Alteration of the DNA Damage Response in Chronic Myeloid Leukemia (2019) (0)
ORIGINAL ARTICLE Antileukemic activity of the HSP70 inhibitor pifithrin-l in acute leukemia (2011) (0)
Abstract #4394: Lnk expression in leukemia cells (2009) (0)
Response Signature to the CD95-Ligand Inhibitor Asunercept Involve Low Serum P53 and Rankl (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Wolf-karsten W.-k. Hofmann?

Wolf-karsten W.-k. Hofmann is affiliated with the following schools:

Heidelberg University

Wolf-karsten W.-k. Hofmann's Academic­Influence.com Rankings

Wolf-karsten W.-k. Hofmann's Degrees

Why Is Wolf-karsten W.-k. Hofmann Influential?

Wolf-karsten W.-k. Hofmann's Published Works

Published Works

What Schools Are Affiliated With Wolf-karsten W.-k. Hofmann?

Wolf-karsten W.-k. Hofmann's AcademicInfluence.com Rankings